Mepenzolate (bromide)

Mepenzolate bromide is an orally administered muscarinic receptor antagonist with Kis of 0.68 and 2.6 nM for hM2R and hM3R, respectively. Mepenzolate bromide can be used to suppress the gastrointestinal hypermotility associated with irritable bowel syndrome[1].Mepenzolate bromide is a GPR109A inhibitor[2].

Product Specifications

CAS Number

[76-90-4]

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

GPR109A; mAChR

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Inflammation/Immunology; Others

Assay Protocol

https://www.medchemexpress.com/Mepenzolate-Bromide.html

Concentration

10mM

Purity

99.90

Solubility

DMSO : 250 mg/mL (ultrasonic) |H2O : 10 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C[N+]1(C)CC(OC(C(C2=CC=CC=C2)(O)C3=CC=CC=C3)=O)CCC1.[Br-]

Molecular Formula

C21H26BrNO3

Molecular Weight

420.34

Precautions

H302, H312, H332

References & Citations

[1]Yasunobu Yamashita, et al.Synthesis and biological comparison of enantiomers of mepenzolate bromide, a muscarinic receptor antagonist with bronchodilatory and anti-inflammatory activities. Bioorg Med Chem. 2014 Jul 1;22 (13) :3488-97.|[2]Hesham Aly Salem, et al. Effect of Niacin on Inflammation and Angiogenesis in a Murine Model of Ulcerative Colitis. Sci Rep. 2017 Aug 2;7 (1) :7139.|[3]Ken-Ichiro Tanaka, et al. Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease. Nat Commun. 2013;4:2686.